The Bob Harrington Show

#44: Improving patient adherence to medication with Dr Eric Peterson

info@theheart.org — Mon, 09 Jan 2012 15:45:00 -0500

Patient adherence to medication has long defied quantification, with many physicians assuming that the cost of medications is the primary factor explaining poor rates of compliance. How do we explain abysmal rates of patient adherence to medication?

#43: Same-day discharge from the hospital after elective PCI with Dr Sunil Rao

info@theheart.org — Wed, 07 Dec 2011 14:30:00 -0500

What is the best way to care for patients following PCI? Is same-day discharge a viable—or even desirable—option? Dr Sunil Rao joins the show to discuss his recent paper in JAMA, including the background for the study, source of data, and methodology.

#42: Statins--Cardiovascular benefit vs diabetes risk with Dr Michael Cobble

info@theheart.org — Tue, 01 Nov 2011 10:35:00 -0400

Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes?

#41: The ISCHEMIA trial on optimal care for patients with stable coronary disease with Dr...

info@theheart.org — Thu, 06 Oct 2011 10:20:00 -0400

The large ISCHEMIA trial, led by Dr Judith Hochman, seeks to build on the results of COURAGE and BARI 2D to answer the important question: what is the best treatment for patients with stable coronary disease?

#40: The civility of professional discourse with Dr Clyde Yancy

info@theheart.org — Mon, 12 Sep 2011 14:15:00 -0400

With the multiplication of methods of communication, the democratization of access to information, and the fast pace of today's technology it's hard not to feel that professional discourse has taken a bashing and that civility in discourse is a lost art.

#39: The uptake of clinical trial findings: Focus on OAT with Dr David Kandzari

info@theheart.org — Wed, 10 Aug 2011 15:25:00 -0400

Recent reports indicate that the Occluded Arteries Trial (OAT)—while continuing to stir debate—has made little impact on clinical practice among US physicians. What explains this situation?

#38: HDL cholesterol, niacin, and AIM-HIGH with Dr Jim Stein

info@theheart.org — Wed, 06 Jul 2011 15:05:00 -0400

Is the concept of raising HDL cholesterol still pertinent in an era of well-controlled LDL levels via statin therapy? To address this question, our guest Dr Jim Stein reviews what evidence exists to indicate low HDL cholesterol may predict heart disease..

#37: Reversible anticoagulation in RADAR with Dr Thomas Povsic

info@theheart.org — Thu, 02 Jun 2011 08:35:00 -0400

Reversible anticoagulation may open the door to more efficacious treatment and better outcomes in settings such as PCI and valve replacement, as well as bypass surgery. But how does the risk of bleeding fit into the equation? Dr Thomas Povsic discusses.

#36: Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone

info@theheart.org — Mon, 09 May 2011 16:25:00 -0400

Antiplatelet responsiveness and personalized medicine: Lessons from GRAVITAS and TRIGGER-PCI with Dr Gregg Stone

#35: Oral antithrombotic agents: An update for the clinical practitioner with Dr Jonathan Halperin

info@theheart.org — Thu, 14 Apr 2011 15:15:00 -0400

After decades of reliance on warfarin, there are finally new options for oral anticoagulation, with exciting results from the RE-LY, ROCKET, and AVERROES trials paving the way for dabigatran, rivaroxaban, and apixaban.

#34: Healthcare reform update: Clinical and business implications for cardiologists

info@theheart.org — Wed, 30 Mar 2011 14:50:00 -0400

Where does healthcare reform stand, and what are the implications for cardiologists? Physician and business leader Dr Kevin Schulman joins the show to help clarify the healthcare debate and shine light on how the new Congress ...

#33: Quality assurance in cardiology with Dr John Rumsfeld

info@theheart.org — Thu, 10 Feb 2011 16:25:00 -0500

Quality assurance—or appropriate use of cardiology procedures—is a hot topic that defies simple quantification and has important ramifications for patients, healthcare professionals, and society at-large. Join Dr John Rumsfeld.

#32: Advances in heart-failure research with Dr Clyde Yancy

info@theheart.org — Mon, 10 Jan 2011 16:05:00 -0500

Advances in heart-failure research with Dr Clyde Yancy. Heart-failure is estimated to account for two million hospital admissions per year in the US, based on primary and secondary diagnosis.

#31: Atkins, diet, obesity, and cardiovascular disease risk with Dr Eric Westman

info@theheart.org — Fri, 17 Dec 2010 10:20:00 -0500

Atkins, diet, obesity, and cardiovascular disease risk with Dr Eric Westman. Hotly debated among healthcare professionals, "low-carb" diets—such as Atkins—have soared in popularity, offering easy-to-follow approaches and rapid results. But are they safe?

#30: Canadian antiplatelet guidelines with Dr Alan Bell

info@theheart.org — Fri, 03 Dec 2010 11:35:00 -0500

Notable for their therapy-based approach, rigor, and clarity, the Canadian Cardiovascular Society (CCS) antiplatelet guidelines were recently presented by coauthors Drs Alan Bell and Jean-François Tanguay at the CCS annual meeting in Montreal.

#29: Obesity in America with Dr Thad Waites

info@theheart.org — Mon, 01 Nov 2010 11:05:00 -0400

According to the Center of Disease Control, 72.5 million Americans are obese (with a body-mass index [BMI] >30), and 27% of the increase in healthcare costs is related to the treatment of obesity. Dr Thad Waites joins the show to discuss.

#28: AVERROES: Apixaban as a future alternative to warfarin with Dr Stuart Connolly

info@theheart.org — Thu, 07 Oct 2010 16:15:00 -0400

The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists.

#27: Elinogrel and INNOVATE PCI with Dr Sunil Rao

info@theheart.org — Tue, 07 Sep 2010 11:55:00 -0400

From the European Society of Cardiology 2010 Congress, Dr Sunil Rao gives an overview of the field of antiplatelet therapy, reviews the key features of elinogrel, and discusses the design, features, and findings of INNOVATE PCI.

#26: Dissecting the controversy around JUPITER with Dr Paul Ridker

info@theheart.org — Fri, 20 Aug 2010 14:30:00 -0400

Hailed as a landmark trial by many, JUPITER has spawned a vociferous cadre of detractors whose assertions have stirred debate and some controversy throughout the cardiovascular community. Dr Paul Ridker joins the show to dissect the controversy.

#25: Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel

info@theheart.org — Tue, 03 Aug 2010 09:05:00 -0400

There has been much research, press, and some controversy in the rapidly evolving sphere of antiplatelet therapy—culminating in the FDA's black-box warning on clopidogrel. Dr Paul Gurbel joins the show to clarify the core issues; review key terms such as hypo- and hyper-responsiveness and resistance and nonresponsiveness; discuss the roles and relative importance of genotyping vs phenotyping; and ponder how the GRAVITAS and TRIGGER PCI trials may help to lead the way forward for antiplatelet therapy.

What are your thoughts on the FDA's black-box warning on clopidogrel? What roles do you see for genotyping and phenotyping for platelet responsiveness?

See:

New meta-analysis: CYP2C19*2 carriers at higher risks of events on clopidogrel

Personalizing antiplatelet therapy: Could platelet-function tests help?

Cardiologists voice concern on FDA clopidogrel warning

The FDA and clopidogrel: Caution or confusion?

RESPOND: Ticagrelor improves platelet inhibition in both clopidogrel responders and nonresponders